



UHI Research Database pdf download summary

Intermittent exposure of cultured endothelial cells to physiologically relevant fructose concentrations has a profound impact on nitric oxide production and bioenergetics

Fiorello , Maria; Treweeke, Andrew; Megson, Ian; Macfarlane, David

Published in:
PLOS ONE

Publication date:
2022

Publisher rights:
Copyright © 2022 The Authors

The re-use license for this item is:
CC BY

The Document Version you have downloaded here is:
Peer reviewed version

The final published version is available direct from the publisher website at:
[10.1371/ journal.pone.0267675](https://doi.org/10.1371/journal.pone.0267675)

[Link to author version on UHI Research Database](#)

Citation for published version (APA):

Fiorello , M., Treweeke, A., Megson, I., & Macfarlane, D. (2022). Intermittent exposure of cultured endothelial cells to physiologically relevant fructose concentrations has a profound impact on nitric oxide production and bioenergetics. *PLoS ONE*, Article e0267675. <https://doi.org/10.1371/journal.pone.0267675>

General rights

Copyright and moral rights for the publications made accessible in the UHI Research Database are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights:

- 1) Users may download and print one copy of any publication from the UHI Research Database for the purpose of private study or research.
- 2) You may not further distribute the material or use it for any profit-making activity or commercial gain
- 3) You may freely distribute the URL identifying the publication in the UHI Research Database

Take down policy

If you believe that this document breaches copyright please contact us at RO@uhi.ac.uk providing details; we will remove access to the work immediately and investigate your claim.

1 Intermittent exposure of cultured endothelial cells to physiologically relevant fructose concentrations
2 has a profound impact on nitric oxide production and bioenergetics
3

Formatted: No Spacing, Line spacing: single

4

5 Maria Luisa Fiorello¹, Andrew T Treweeke¹, David P Macfarlane², Ian L Megson^{1*}

6

7

8 ¹Division of Biomedical Sciences, University of the Highlands & Islands, Inverness, UK

9 ²Department of Diabetes, NHS Highland, Raigmore Hospital, Inverness, UK

10

11 *Corresponding author

12

13 e-mail: ian.megson@uhi.ac.uk (ILM)

14

1

2 **Abstract**

3 Hyperglycaemia is known to induce endothelial dysfunction and changes in metabolic
4 function, which could be implicated in diabetes-induced cardiovascular disease. To date,
5 however, little is known about the impact of physiologically relevant concentrations of
6 fructose on endothelial cells.

7 A novel *in vitro* model was devised to establish the impact of substitution of a small
8 proportion of glucose with an equal concentration (0.1 mM or 1 mM) of fructose on
9 EA.hy926 endothelial cells during periodic carbohydrate “meals” superimposed on a
10 normoglycaemic (5.5 mM) background. Parallel experiments were conducted using meals
11 consisting of normoglycaemic glucose, intermediate glucose (12.5 mM) or profound
12 hyperglycaemia (25 mM), each delivered for 2 h, with and without substituted fructose over
13 50 h. Outcome measures included nitrite as a surrogate marker of the mediator of healthy
14 endothelial function, nitric oxide (NO), and a range of bioenergetic parameters using a
15 metabolic analyser.

16 Despite its relatively low proportion of carbohydrate load, intermittent fructose induced a
17 substantial reduction (approximately 90%) in NO generation in cells treated with either
18 concentration of fructose. Cell markers of oxidative stress were not altered by this
19 treatment regimen. However, the cells experienced a marked increase in metabolic activity
20 induced by fructose, irrespective of the glucose concentration delivered simultaneously in
21 the “meals”. Indeed, glucose alone failed to induce any metabolic impact in this model. Key
22 metabolic findings were a 2-fold increase in basal oxygen consumption rate and a similar
23 change in extracellular acidification rate – a marker of glycolysis. Non-metabolic oxygen

1 consumption also increased substantially in cells exposed to fructose. There was no
2 difference between results with 0.1 mM fructose and those with 1 mM fructose.
3 Low, physiologically relevant concentrations of fructose, delivered in a pattern that mimics
4 mealtime consumption, had a profound impact on endothelial function and bioenergetics in
5 an *in vitro* cell model. The results suggest that endothelial cells are exquisitely sensitive to
6 circulating fructose; the potential ensuing dysfunction could have major implications for
7 development of atherosclerotic disease associated with high fructose consumption.

8

9 **Keywords**

10 Bioenergetics; endothelial cells; fructose; metabolism; nitric oxide

11

12

13

14

15

16 **Introduction**

17 A functional endothelium is essential for cardiovascular health [\[1\]](#). The endothelium
18 represents the interface between the blood and the surrounding tissues [\[2\]](#) and is
19 therefore exposed to unbuffered variations in blood-borne nutrients. Hyperglycaemia, the
20 hallmark of both type 1 and type 2 diabetes, induces endothelial dysfunction, leading to
21 macro- and microvascular complications [\[3,4\]](#). Both persistent hyperglycaemia and

1 intermittent glycaemic excursions are known to induce endothelial dysfunction [\(5–8\)](#)[\[5–8\]](#),
2 mediated by oxidative stress [\(9,10\)](#)[\[9,10\]](#), advanced glycated end-product (AGE) formation,
3 epigenetic modifications [\(11–13\)](#)[\[11–13\]](#) and generation of a pro-inflammatory phenotype
4 [\(7,14,15\)](#)[\[7,14,15\]](#). The long-term impact of hyperglycaemia, even when followed by relative
5 normoglycaemia, has been demonstrated in clinical trials, such as the Diabetes Control and
6 Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC
7 and the UK Prospective Diabetes Study (UKPDS) [\(16\)](#)[\[16\]](#) and in animal studies [\(17\)](#)[\[17\]](#). A
8 recent *in vitro* study [\(Fiorello et al. 2020\)](#)[\[18\]](#) showed how endothelial metabolism and
9 redox status are rewired by long-term oversupply of glucose, leading to a more quiescent
10 cellular state and decreased superoxide dismutase (SOD) activation, effects that were not
11 reversible after 48 hours of glucose normalisation.

12

13 The monosaccharide, fructose, is commonly ingested with glucose in the Western diet,
14 either as part of the disaccharide, sucrose, or in high fructose corn syrup, fruit and honey
15 [\(18\)](#)[\[19\]](#). Although fructose was once considered to be a desirable substitute for glucose in
16 diabetes patients due to its low glycaemic index (GI) (GI=23, versus GI=100 for glucose) [\(19–](#)
17 [21\)](#)[\[20–22\]](#), the increase in fructose consumption over the last 40 years has instead been
18 associated with an increase in metabolic syndrome [\[\(23,24\)\]](#). Whilst this effect has been
19 postulated to be in part related to an overall increase in energy intake, there is clear
20 evidence that fructose can directly lead to adverse metabolic effects. The liver is responsible
21 for the metabolism of approximately 70% of the total fructose absorbed [\(24\)](#)[\[25\]](#) and,
22 conversely to glucose, hepatic fructose metabolism is unregulated, leading to adverse
23 effects, such as increased *de novo* lipogenesis [\[\(26,27\)\]](#), AGE formation [\(27–29\)](#)[\[28–30\]](#),

1 cellular ATP depletion and an increase in uric acid generation [\(30–32\)](#)[\[31–33\]](#). These aspects
2 are exacerbated in the presence of other risk factors for poor health, such as type 2 diabetes
3 [\(33,34\)](#)[\[34,35\]](#), leading to a greater risk of cardiovascular complications. Contemporary
4 administration of fructose and glucose leads to increased risk of developing non-alcoholic
5 fatty liver disease and dyslipidaemia [\(25,35,36\)](#)[\[26,36,37\]](#), by reducing glucose oxidation and
6 gluconeogenesis, while increasing metabolic intermediates that fuel *de novo* lipogenesis
7 (DNL) and the triglyceride precursor, glycerol-3—phosphate [\(37,38,38,39\)](#), as well as gene
8 expression and activation of lipogenic enzymes [\(39,40\)](#)[\[40,41\]](#).

9
10 Fructose can reach concentrations of up to 1 mM post-prandially [\(41,42\)](#)[\[42,43\]](#). Recent
11 studies have identified inflammation, inhibition of nitric oxide (NO) production [\(43\)](#)[\[44\]](#), a
12 prothrombotic phenotype [\(44\)](#)[\[45\]](#), oxidative stress [\(45\)](#)[\[46\]](#), increased endothelial cell
13 senescence [\(46,47\)](#) and augmented formation of intracellular and extracellular AGEs
14 [\(27\)](#)[\[28\]](#) to be the most important effects associated with fructose consumption. However,
15 there is currently a lack of understanding of the impact of systemic fructose on endothelial
16 cells, and little is known about the capacity of endothelial cells.

17
18 This study set out to investigate the effect of combined exposure of cultured endothelial
19 cells to glucose and fructose, delivered at physiologically relevant concentrations and
20 frequencies. It was hypothesised that fructose exposure detrimentally affects the availability
21 of NO and alters metabolism in endothelial cells.

22

1 Cell culture has a great deal to offer this subject area, but equally presents a number of
2 challenges with respect to recreating scenarios that accurately reflect the *in vivo* situation.
3 For example, cells are often traditionally grown under very high glycaemic conditions (25
4 mM) that would rarely be found in even the most poorly controlled patient with diabetes.
5 Additionally, in the vast majority of *in vitro* experimental models, alterations in glucose
6 conditions applied to cells are continued for many hours or days that do not reflect post-
7 prandial excursions, while glucose-induced changes in osmolarity are not often mitigated. In
8 an extension to our previous endothelial model for hyperglycaemia [(4718)], this study
9 implemented a novel model that was designed to more closely mimic postprandial glucose
10 oscillations in cells grown through multiple passages under normo-glycaemic conditions,
11 whilst at the same time maintaining constant osmolarity by balancing with mannitol.

12

13 **Materials and Methods**

14 **Materials**

15 Unless stated otherwise, all chemicals were purchased from Sigma Aldrich (Dorset, UK). Cell
16 culture consumables were purchased from VWR (Lutterworth, UK).

17

18 **Cell culture and treatments**

19 The endothelial cell line, EA.hy926 (ATCC CRL-2922; a commercially available fusion of
20 primary human umbilical vein cells with a clone of A549 cells), was cultured in Dulbecco's
21 Modified Eagle's Medium (DMEM; HyClone) containing 5.5 mM glucose, 2 mM L-glutamine,

1 5% penicillin/streptomycin (10000 Units/mL and 10 mg/mL) and 10% foetal bovine serum, in
2 a humidified atmosphere at 37°C and 5% CO₂. Cells pre-conditioned to 5.5 mM glucose
3 through several (>5) passages were chosen for this study because those grown under
4 traditional conditions (25 mM) glucose were previously found to be refractory to acute
5 glycaemic changes [\[4718\]-1](#). Cells were seeded at 2x10⁴ cells/well in standard 96 well plates
6 for nitrite and ROS analysis and in specialised Seahorse XF96 cell culture 96-well microplates
7 for metabolic analysis. In both cases, cells were incubated for 12 hours (37°C, 5% CO₂) to set
8 down prior to initiation of the experimental protocol.

9

1 **Glucose and [glucose+fructose] treatments**

2 **Glucose only model**

3 In the basic, glucose only model, cells preconditioned to normoglycaemic (NG; 5.5 mM)
4 conditions were exposed to intermediate hyperglycaemia (IG; 12.5 mM) and extreme
5 hyperglycaemia (HG; 25 mM) as the exclusive carbohydrate source in intermittent
6 exposures of 2 hours each, delivered at times designed to mimic breakfast (08:00-10:00),
7 lunch (13:00-15:00) and dinner (18:00-20:00), interspersed with episodes of
8 normoglycaemia. This regime was implemented for up to 50 hours, with two overnight
9 (20:00 – 08:00) “fasts”, during which NG conditions were maintained (Figure 1). A NG
10 control regimen was included to represent exceptional glycaemic control and iso-osmolarity
11 was maintained throughout with a balance of mannitol (Table 1). For practical reasons,
12 supernatant for nitrite was taken after the second 12 h overnight fast to ensure
13 accumulation of sufficient nitrite for measurement; the cells in these plates, however, went
14 on to a further meal exposure and were then used for ROS/superoxide analysis. Parallel
15 experiments conducted in specialised Seahorse XF96 cell culture 96-well microplates for
16 metabolic analysis were also exposed to the final mealtime carbohydrate exposure before
17 undergoing the mito- stress test outlined below.

18

19 **Fig 1. Representation of the experimental regimens for EA.hy926 cells (glucose only model**
20 **– top panel; glucose+fructose – bottom panel).** The total treatment time was 50 h,
21 incorporating 7 treatment periods at intervals designed to mimic popular mealtimes in human
22 populations. Two parallel sets of experiments were undertaken: cells destined for metabolic
23 analysis were cultured in specialized 96 well microplates for this purpose; analysis was

1 undertaken at the end of the 50 hour treatment period. Cells destined for ROS/superoxide
2 analysis were cultured in standard 96 well microplates. Supernatant was harvested after 48 h
3 for nitrite analysis, while ROS/superoxide analysis was conducted on the cells after the final
4 2 h meal exposure.

5

6 **Glucose + Fructose model**

7 To test the impact of physiologically relevant substitution of a component of glucose load
8 with fructose, a modification of the basic glucose only protocol was employed. Here, cells
9 preconditioned under normoglycaemic conditions were exposed to the same pattern of
10 hyperglycaemic episodes, but this time a portion (0.1 mM or 1 mM) of the glucose was
11 replaced with fructose (Table 1). The concept was to mimic mealtimes that included fructose
12 ingestion. All other aspects of the experiments were identical to the basic model, including
13 interspersed periods of normoglycaemia (without fructose), an overnight fast, iso-osmolarity
14 maintained through balanced mannitol and a normoglycaemic control arm, in which
15 mealtime treatments consisted of 4.5 mM glucose + 1 mM fructose or 5.4 mM glucose + 0.1
16 mM fructose. In keeping with our previous work, cells typically reached confluence during
17 the 48 h treatment regimens.

18

19

20

21

22

23

24

1 **Table 1. Composition of test glucose and glucose/fructose medium for the intermittent**
2 **treatment.**

3

Total carbohydrate concentration	Glucose only	Glucose concentration with 0.1 mM fructose	Glucose concentration with 1 mM fructose	Osmolarity control (mannitol)
NG (5.5 mM)	5.5 mM	5.4 mM	4.5 mM	19.5 mM
IG (12.5 mM)	12.5 mM	12.4 mM	11.5 mM	12.5 mM
HG (25 mM)	25 mM	24.9 mM	24 mM	0 mM

4 NG: normal glucose; IG: intermediate glucose; HG - hyperglycaemic

5

6 **Outcome measures**

7 **Nitrite accumulation**

8 Supernatant from cells in both models was collected after the overnight fast (i.e. 12 h of
9 accumulation) for nitrite analysis, by way of a marker of nitric oxide (NO) production using a
10 Sievers 280i nitric oxide analyser (NOA). Medium from a triplicate for each condition (n=9-
11 14 independent experiments for each) was pooled into a single tube and stored at -80°C.
12 Prior to analysis, batched test samples were defrosted on ice and diluted 1 in 4 in deionized
13 water. For each sample, 100 µl was injected into the NOA chamber containing 4.5 ml of
14 glacial acetic acid (Fisher Scientific), 100 µl of dilute antifoam B emulsion and 0.5 ml of

1 sodium iodide (25 mg/ml; Fisher Scientific). Medium only samples for each condition were
2 used as background controls. Data were acquired using Liquid Software (Version 2),
3 integrated and the sample nitrite values extrapolated from the standard curve.

4

5 **Metabolic analysis**

6 The bioenergetic phenotype of the cells at the end of the treatment period was determined
7 using a Seahorse Bioscience XF^e96 Extracellular Flux Analyzer (Agilent) to measure both the
8 oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) using the
9 Seahorse mito-stress test (MST; Agilent). The assay was performed according to the
10 manufacturer's instructions and all Seahorse-related kits, reagents and consumables were
11 purchased from Agilent unless stated.

12

13 The EA.hy926 cells were observed to be fully confluent at the end of the 50 hour treatment
14 period and immediately prior to the MST assay. Medium was removed from each well, the
15 cells washed twice with Seahorse assay medium (Seahorse XF Base Medium containing 1
16 mM pyruvate, 2 mM L-glutamine and 10 mM glucose, adjusted to pH 7.4), prior to
17 incubation at 37°C for 45 minutes in a CO₂-free incubator during which basal and then real-
18 time changes in OCR and ECAR were monitored following three sequential injections of
19 mitochondrial electron transport chain (ETC) modulators: first, oligomycin (1 μM; complex V
20 inhibitor); next carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP, 1 μM; an
21 uncoupler of mitochondrial oxidative phosphorylation) and finally a combination of
22 rotenone and antimycin A (both 0.5 μM), to inhibit complex I and complex III respectively.

1 All injectable treatments were freshly prepared, loaded into the injection ports and the
2 sample plate loaded into the Seahorse XF[®]96 for analysis. Data acquisition started from the
3 third measurement of each cycle and was analysed using Seahorse Wave Software (Version
4 2.6.0.31).

5
6 At the end of the assay, the protein content of each well was quantified using a Coomassie-
7 Bradford-Protein Assay Kit (Merck, Sigma Aldrich), to allow for normalisation of data per mg
8 of protein present in the well. Cells were lysed *in situ* with distilled water and repeated
9 freeze-thaw cycles. This protein estimate assay was subsequently used as a surrogate for
10 cell density where removal of cells for counting was not practical.

11

12 **Total reactive oxygen species-reactive nitrogen species (ROS-RNS) assay**

13 The total ROS-RNS and superoxide detection fluorescent assay (Enzo Life Sciences, UK) was
14 used to estimate the ROS-RNS production of EA.hy926 cells seeded in a 96-well plate (2×10^4
15 cells/well) and treated for 50 hours with NG, IG or HG medium, according to the protocol
16 illustrated in Fig 1. Pyocyanin was used as a positive control for induction of ROS (200 μ M
17 for 20 min) and all treatments were made in triplicate. The assay was performed according
18 to the kit instructions and the fluorescent signal detected (excitation/emission $\lambda=488/520$
19 nm) using a VarioScan plate reader (Thermo-Fisher) with SkanIt Software 2.4.5 (Varioskan
20 Flash). All results were normalized to the protein content of each well.

21

1 **Statistics**

2 All data are expressed as mean \pm SD unless otherwise stated; individual points on each
3 graph indicate independent experiments. Data were analysed using appropriate parametric
4 and non-parametric tests, as defined by normality (D'Agostino and Pearson test) and equal
5 variance testing. Significant difference between means was accepted at $P < 0.05$. Statistical
6 tests were performed using GraphPad Prism version 6.00 software (GraphPad Software, San
7 Diego, CA). Details of tests used are included in each figure legend; data were treated as
8 unpaired in all data sets.

9

10

11

12 **Results**

13 **Effect of glucose/fructose exposure on NO generation, index of** 14 **endothelial cell function**

15 Inclusion of fructose (both 0.1 mM and 1 mM) during intermittent exposure caused a
16 profound decrease in nitrite accumulation, irrespective of the glucose concentration (Fig 2),
17 despite relatively high variance in some of the datasets, which is not unusual for NO
18 assessments. There was no significant difference between the data from experiments
19 involving 0.1 mM fructose compared to 1 mM fructose ($P > 0.05$; 2 Factor ANOVA with
20 Bonferroni post-test). It is important to note that the nitrite measured was accumulated
21 nitrite over the 12 h overnight period with 5.5 mM glucose and no fructose present. In

1 addition, exposure to intermittent hyperglycaemia (12.5 mM or 25 mM) failed to have any
2 impact on overnight nitrite accumulation.

3

4 **Fig 2. Nitrite accumulation as a surrogate for NO generation.** Effect of intermittent glucose
5 and glucose/fructose exposure on nitrite accumulation at NG, IG and HG test conditions
6 (n=12-14; ***P<0.001 Bonferroni post-test compared to glucose only control at equivalent
7 concentrations).

8

9 **Effect of glucose/fructose exposure on cell bioenergetics**

10 Overall, cells treated with the glucose/fructose combinations showed a marked increase in
11 oxygen consumption over cells treated with glucose alone (Fig 3). At each of the three
12 carbohydrate concentrations, basal OCR (Figure 3A), complex V OCR (Fig 3B) and maximum
13 OCR (Fig 3C) values were markedly elevated to a similar extent (approximately 2-fold) for
14 both 0.1 and 1 mM fructose substitution of glucose compared to glucose only treatments.
15 Increasing glucose alone during the loading periods had no significant effect on any of these
16 parameters (P>0.05; 2-factor ANOVA). By contrast, proton leak increased with glucose
17 concentration during loading episodes (2.5-fold between 5.5 mM and 25 mM), whereas
18 fructose had only a small but significant (P<0.05; two-factor ANOVA) effect (Fig 3D). NMOCR
19 was increased only with 1 mM substituted fructose treatments compared to equivalent
20 glucose only treatments (~1.5 fold increase; Fig 3E). Fructose substitution of glucose also
21 caused an increase in basal ECAR (1.5 – 2-fold) for all combinations (Figure 3F); there was no
22 differential impact of 0.1 mM and 1 mM fructose on ECAR. These data suggest that overall,
23 the presence of even relatively low concentrations of fructose induces greater oxygen

1 consumption and glycolysis, irrespective of the glucose concentration co-existing during the
2 periodic treatments.

3

4 **Fig 3. Cellular Bioenergetics.** Effect of intermittent glucose (G only)/glucose+fructose
5 (G+0.1F, G+1F) exposure on cellular bioenergetics, described by (A) basal OCR, (B) complex
6 V OCR, (C) maximal respiration, (D) proton leak, (E) NMOCR and (F) ECAR. Data are shown as
7 mean \pm SD for n=6-8 separate experiments. Means are compared using 2-factor ANOVA with
8 Bonferroni post-test. ***P<0.001; **P<0.01 for fructose-treated cells compared to glucose
9 only treated cells with the same carbohydrate load. For proton leak, there was a significant
10 impact of carbohydrate load (P<0.001) and of fructose (main effect, P<0.05). For D only:
11 ***P<0.001 and **P<0.01 v equivalent bar at 5.5 mM load; ###P<0.001 and ##P<0.01 v
12 equivalent bar at 12.5 mM load.

13

14 The mean values of basal OCR and basal ECAR were used to create energy maps to identify
15 changes in cell bioenergetic phenotype (Fig 4), which shows that intermittent
16 glucose/fructose treatment generated a more 'energetic' metabolic phenotype (increased
17 oxygen consumption and glycolysis) compared to those treated with intermittent glucose
18 only; this was evident for NG, IG and HG treatments, using both fructose concentrations
19 (Figure 3). Specifically, the presence of fructose resulted in a shift along the
20 energetic/quiescent axis, but not the aerobic/glycolytic axis. There was no detectable
21 impact of intermittent glucose excursions in the absence of fructose.

22

1 **Fig 4. Energy map.** Energy map for cells treated with intermittent glucose and
2 glucose/fructose. Dotted lines represent the direction of change induced by fructose
3 substitution for glucose (0.1 mM – light symbols; or 1 mM – dark symbols) in cells treated
4 with different glucose concentrations. Data are expressed as mean \pm SEM (n=8-12 for each
5 mean depicted).

6

7 **Effect of glucose/fructose exposure on measures of oxidative stress-** 8 **associated parameters**

9 The total ROS-RNS for cells subjected to intermittent glucose exposure had similar values
10 under NG, IG and HG intermittent treatments (0.15 ± 0.03 , 0.14 ± 0.03 and 0.17 ± 0.03
11 AU/mg protein respectively; Fig 5 A; $P > 0.05$). Similarly, superoxide was only modulated by
12 intermittent glucose exposure to IG (Fig 5 B). Inclusion of fructose (0.1 mM, 1 mM) with
13 glucose (NG, IG, HG) had no significant impact on ROS/RNS or superoxide (Fig 5).

14

15 **Fig 5. ROS generation.** Effect of intermittent glucose and glucose/fructose exposure on total
16 ROS-RNS (A) and superoxide (B; n=7-12; # $P < 0.05$ compared to 5.5 mM glucose alone).

17

18

1 **Discussion**

2 This study utilised a novel experimental intermittent carbohydrate exposure model,
3 designed to mimic diurnal glycaemic oscillations. The data presented show that endothelial
4 exposure to physiologically relevant concentrations of fructose had a profound impact on
5 NO generation and cellular metabolism that was not replicated by intermittent
6 hyperglycaemia in the absence of fructose in the same model. The results highlight the
7 potential importance of post-prandial fructose overspill from first-pass hepatic clearance on
8 endothelial function and bio-energetics, independent of any potential indirect effects of
9 fructose (e.g. dyslipidaemia).

10

11 **Endothelial function**

12 NO is a key determinant of endothelial function and was therefore measured in this study in
13 the form of its surrogate, nitrite. The results showed that intermittent exposure to 0.1 and 1
14 mM fructose caused a profound inhibition (approximately 80-90% reduction) of nitrite
15 accumulation, irrespective of the underlying glucose concentration. The lack of impact of
16 the same treatment on ROS and superoxide generation suggests that the effect is not
17 mediated by oxidative loss to peroxynitrite; instead it points to dysfunctional eNOS or
18 pertinent activation pathways, including inhibitory post-translational modifications (such as
19 excessive glycation) or reduced availability of NADPH, Ca²⁺ or tetrahydrobiopterin,
20 necessary for eNOS-mediated NO synthesis [\[\(44,48,49\)\]](#). What is clear is that the effect was
21 not reversed by a 12 h interval between removal of fructose and collection of supernatant
22 for nitrite analysis, suggesting that if the effect is replicated *in vivo*, then these data show a

1 potentially deleterious consequence associated with fructose overspill into the vascular
2 system, which could impair cardiovascular health by increasing atherogenic risk ~~(50–52)~~[\[50–](#)
3 [52\]](#). Of note is that intermittent hyperglycaemia induced by glucose alone failed to impact
4 NO at all. This is contrary to our previous findings involving continuous exposure to 25 mM
5 glucose over a 48 h period, whereby an inhibition of similar magnitude to that found for
6 fructose was observed ~~([1847]–)~~[\[1847\]–](#). It seems, therefore, that both glucose and fructose have
7 the capability to reduce NO synthesis substantially, but that fructose can effect this impact
8 at considerably lower concentrations and reduced exposure time than is the case for
9 glucose.

10

11 **Bioenergetics**

12 The energy map clearly indicates that cellular exposure to fructose resulted in cellular
13 metabolic activation, with an increase in both oxidative phosphorylation (increased OCR,
14 most notably complex V-related OCR) and glycolysis (increased ECAR).

15

16 The increase in maximal OCR achieved with FCCP-mediated disruption of the proton
17 gradient across the inner mitochondrial membrane reflects an increase in cellular
18 mitochondrial efficiency, an adaptation mechanism activated in response to the enhanced
19 electron flux from glucose/fructose treatment via glycolysis and the tricarboxylic acid (TCA)
20 cycle. This increase in maximal OCR could be achieved by either greater transcription of
21 genes encoding ETC complexes, post-translational activation of the complexes, or
22 mitochondrial biogenesis ~~(53)–~~[\[53\]](#). This mechanism could maintain an optimal level of

1 ROS, allowing more mitochondria to share the electron load in the form of reducing
2 equivalents, (NADH and FADH₂) during glycolysis and in the TCA cycle [\(54\)\[54\]](#), a finding that
3 has been identified previously in a similar cell culture models [\(\[47-18,56\]\)](#) and attributed to
4 the Crabtree effect [\(55-57\)\[55-57\]](#).

5
6 It is not clear whether an increase in aerobic metabolic activity observed with intermittent
7 fructose exposure would be deleterious *in vivo*. However, due to the glycolytic nature of
8 endothelial cells, dysregulation of cellular metabolism is likely to represent a disturbance in
9 the homeostatic state of the cells. For example, an increase in metabolism in endothelial
10 cells has been observed in atherosclerosis, as well as during angiogenesis [\(58,59\)\[58,59\]](#).

11 The switch to more aerobic glucose and fructose metabolism could represent a functional
12 disadvantage for the endothelium; greater oxygen consumption or requirement could
13 deprive oxygen release to the perivascular tissues and compromise the ability of endothelial
14 cells to adapt to a less oxygenated environment. Fructose-induced dysregulation of cell
15 metabolism could also result in an imbalance of intracellular redox state, which could, in
16 turn, affect the ability of endothelial cells to produce NO.

17
18 There are a number of mechanisms by which fructose and its metabolites may directly and
19 indirectly influence intracellular bioenergetics and function, including provision of fructose-
20 6-phosphate (F6P) substrate for the aerobic, hexosamine and pentose phosphate pathways.
21 Given that the total carbohydrate load was not different between the glucose only and
22 glucose/fructose arms of this study, and fructose represented only a small fraction of this

1 load, it seems implausible that increased substrate provision is responsible for the
2 substantial changes in metabolism witnessed.

3

4 Unregulated fructose phosphorylation leads to ATP depletion [\[31,32,60\]](#). A consequence of
5 this ATP depletion is adenosine monophosphate-activated protein kinase (AMPK) activation
6 [\[61,62\]\[61,62\]](#), which drives an increase in glycolysis and fatty acid oxidation to restore ATP
7 concentrations [\[63,64\]\[63,64\]](#). As such, the higher mitochondrial oxygen consumption in the
8 presence of fructose (shown by the increase in basal OCR, complex V OCR and maximal OCR)
9 could reflect AMPK activation, in an attempt to restore cellular energy balance. Moreover,
10 ATP depletion and the consequent increase in AMP has been shown to link to uric acid
11 formation, through activation of xanthine oxidase (XO) [\[65\]\[65\]](#), which consumes oxygen,
12 and depresses NO production at the same time as enhancing superoxide, hydrogen peroxide
13 and hydroxyl radical generation [\[66,67\]\[66,67\]](#). Accordingly, the XO inhibitor, allopurinol,
14 has been shown to improve cardiovascular outcomes in patients with type 1 and type 2
15 diabetes [\[68,69\]\[68,69\]](#) and in hyperuricaemic patients [\[70,71\]\[70,71\]](#).

16

17 Fructose-6P can be further phosphorylated in position 2 by phosphofructokinase-2/fructose
18 biphosphatase-2 (PFK2/FBPase-2). The product, fructose 2,6-biphosphate allosterically
19 activates phosphofructokinase 1 (PFK1) [\[72\]\[72\]](#), one of the key glycolytic enzymes, resulting
20 in greater production of glycolytic metabolic intermediates, like triose phosphates
21 (glyceraldehyde-3-phosphate and dihydroxyacetone phosphate). Such products can be
22 further metabolised, via TCA and oxidative phosphorylation, or can participate in alternative

1 glucose metabolic pathways, such as the pentose phosphate pathway and the hexosamine
2 pathway.

3
4 Glucose-6-phosphate dehydrogenase (G6PD), the rate limiting enzyme of the oxidate branch
5 of the pentose phosphate pathway, is important for the production of NADPH [\(73\)\[73\]](#), a
6 cofactor for eNOS-mediated NO synthesis. Therefore an increase in glycolytic intermediates,
7 such as F6P and glyceraldehyde-3-phosphate, and an associated inhibition of G6PD, has the
8 potential to the decrease NO production via this mechanism. In addition, increased flux of F6P
9 through the hexosamine pathway can produce UDP-N-acetylglucosamine (UDPGlcNAc), a
10 substrate for protein regulation by O-linked glycosylation [\(74\)\[74\]](#). Excessive protein O-linked
11 glycosylation can, in turn, contribute to eNOS inactivation [\(75\)\[75\]](#).

12 **Oxidative species production**

13 Proton leak was the only parameter measured in these experiments that increased with
14 intermittent glucose, but was not significantly altered by the presence of fructose. Proton leak
15 is a well-known phenomenon that can be induced by activation of uncoupling proteins,
16 allowing protons to leak back across the inner mitochondrial membrane, reducing the
17 protonmotive force essential for efficient ATP synthase (complex V) activity and uncoupling
18 oxygen utilisation and ATP production. Proton leak is a contributor in endothelial activation
19 in early atherosclerosis [\(76\)\[76\]](#) is one scenario in which increased, although exposure of
20 endothelial cells to oxidative stress is understood to reduce proton leak. The prevailing
21 hypothesis linking proton leak to oxidative stress is that uncoupling reduces ROS generation,
22 perhaps by way of a protective mechanism. Our results perhaps hint at reduced superoxide

1 in cells exposed to hyperglycaemia (12.5 mM in particular) with or without fructose, but a
2 convincing inverse relationship between glycaemic load and ROS is not clear in this model.

3

4 NMOCR is another potential indicator of oxidative stress on account of utilisation of oxygen
5 by ROS-generating enzymes such as cyclo-oxygenases, lipoxygenases and NAD(P)H oxidases.

6 Our results indicate that intermittent exposure to fructose at both 0.1 mM and 1 mM has the
7 capability of greatly increasing NMOCR (~1.5-fold), but this does not correlate with the
8 ROS/superoxide data, which were inconclusive with respect to the impact of fructose.

9

10 In interpreting these data, it is important to consider that the cells were ostensibly healthy
11 and likely capable of mounting an effective counter-regulatory defence in response to an
12 acute, potentially low-level rise in ROS generation. The impact of more prolonged glycaemic
13 insult, or that in cells already in a state of disease-induced oxidative stress, might be more
14 substantial in terms of oxidative damage. The finding that alterations in proton leak
15 (hyperglycaemia) and NMOCR (fructose) are induced in endothelial cells, at least illustrates
16 that there is potential for dysregulation-induced redox impacts.

17

18 **Limitations**

19 Use of an immortalized cell line (EA.hy926) could be seen as a limitation of this study, but was
20 deemed essential because, unlike primary endothelial cells, they are resistant to senescence
21 and de-differentiation through multiple passaging [\(77\)\[77\]](#). Our previous work had clearly
22 illustrated the need for passaging of cells in normoglycaemic conditions to prevent

1 engendering a refractory state; unlike cloned cells, primary cells lose their endothelial cell
2 characteristics through passaging, preventing habituation to normoglycaemia following early
3 passaging in hyperglycaemic medium, which is often the case for primary cells (e.g. HUVECs).
4 In addition, cell culture experiments are always restricted by temporal constraints; the effects
5 seen here were after only 50 h experimental procedures, whereas chronic exposures are likely
6 to induce more substantial and potentially different impacts. Nevertheless, the fact that acute
7 exposures caused such substantial effects in a model that reasonably mimics exposures that
8 might be found in vivo supports the experimental design.

9

10

11 **Conclusions**

12 This study highlights for the first time the effect of intermittent, physiologically relevant (as
13 low as 0.4% of total carbohydrate load) fructose exposure on cultured vascular endothelial
14 cells, and the interaction with concomitant glucose concentrations.

15 Exposure of EA.hy926 cells to a combination of fructose with glucose dramatically increased
16 cellular respiration, while depressing NO production. The metabolic impacts in this regard are
17 substantially greater than an equivalent increase in glucose alone, with the exception of
18 proton leak, which was more clearly modulated by hyperglycaemic episodes and not
19 seemingly impacted by fructose inclusion.

20

21 The findings could have profound implications with respect to dietary fructose intake, (e.g.
22 free fructose, high-fructose corn syrup or sucrose). This is particularly important in the

1 context of diabetes, where chronic hyperglycaemic is known to trigger endothelial
2 dysfunction and increase atherogenic risk [\(50,51\)](#)[\[50,51\]](#). The added complication of
3 increased proton leak on top of modulation of metabolism and reduced NO generation
4 induced by fructose could add to the long-term consequences of fructose ingestion in patients
5 with diabetes. In addition, since fructose absorption is variable among different individuals
6 [\(78,79\)](#)[\[78,79\]](#), monitoring the postprandial blood concentration of fructose as well as glucose
7 may lead to more precise and meaningful, individual lifestyle interventions.

8
9 The next step in understanding these complex processes is to extend this study to primary
10 human cells relevant to atherosclerotic risk, such as human coronary artery endothelial cells.
11 These cells have been shown to express the transporter protein GLUT2 [\(80\)](#)[\[80\]](#), which is
12 responsible for fructose internalisation, and could be used to further explore the effects of
13 fructose metabolism on endothelial cell function and redox state. In addition, a proteomic
14 approach could clarify the underlying mechanisms that drive the fundamental cellular
15 changes observed.

16

17 **Abbreviations**

18 Adenosine triphosphate – ATP; Dulbecco's Modified Eagle's Medium - DMEM; egtazic acid
19 – EGTA; endothelial nitric oxide synthase – eNOS; carbonyl cyanide-4-(trifluoromethoxy)
20 phenylhydrazone - FCCP; high glucose – HG; intermediate glucose – IG; mitochondrial
21 stress test – MST; nitric oxide – NO; non-mitochondrial oxygen consumption rate –
22 NMOCR; normal glucose – NG; oxygen consumption rate – OCR; reactive oxygen species –
23 ROS; reactive nitrogen species – RNS; superoxide dismutase – SOD.

1

2 **References**

- 3 1. Sena CM, Pereira AM, Seça R. Endothelial dysfunction - A major mediator of diabetic
4 vascular disease. *Biochimica et Biophysica Acta - Molecular Basis of Disease*. 2013. 1832:
5 2216–2231. doi: 10.1016/j.bbadis.2013.08.006
- 6 2. Schlag G, Redl H. Endothelium as the interface between blood and organ in the
7 evolution of organ failure. In: *Shock, sepsis, and organ failure*. Springer Berlin Heidelberg;
8 1990. p. 210–271.
- 9 3. Popov D. Endothelial cell dysfunction in hyperglycemia: Phenotypic change,
10 intracellular signaling modification, ultrastructural alteration, and potential clinical
11 outcomes. *Int J Diabetes Mellit*. 2010;2: 189–95. doi: 10.1016/j.ijdm.2010.09.002
- 12 4. Gero D. Hyperglycemia-induced endothelial dysfunction. In: *Endothelial dysfunction -*
13 *old concepts and new challenges*. InTech; 2018. doi: 10.5772/intechopen.71433
- 14 5. Risso A, Mercuri F, Quagliari L, Damante G, Ceriello A. Intermittent high glucose
15 enhances apoptosis in human umbilical vein endothelial cells in culture. *Am J Physiol -*
16 *Endocrinol Metab*. 2001;281: 44-45. doi: 10.1152/ajpendo.2001.281.5.E924
- 17 6. Piconi L, Quagliari L, Assaloni R, Da Ros R, Maier A, Zuodar G, et al. Constant and
18 intermittent high glucose enhances endothelial cell apoptosis through mitochondrial
19 superoxide overproduction. *Diabetes Metab Res Rev*. 2006;22: 198–203. doi:
20 10.1002/dmrr.613

- 1 7. Piconi L, Quagliaro L, Da Ros R, Assaloni R, Giugliano D, Esposito K, et al. Intermittent
2 high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human
3 umbilical endothelial cells in culture: The role of poly(ADP-ribose) polymerase. *J Thromb*
4 *Haemost.* 2004;2: 1453–1459. doi: 10.1111/j.1538-7836.2004.00835.x
- 5 8. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol J-P, et al. Activation of oxidative
6 stress by acute glucose fluctuations compared Wwith sustained chronic hyperglycemia in
7 patients with type 2 diabetes. *JAMA.* 2006 ;295: 1681-1687. doi: 10.1001/jama.295.14.1681
8
- 9 9. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin
10 resistance, diabetes, and cardiovascular disease? the common soil hypothesis revisited.
11 *Arterioscler Thromb Vasc Biol.* 2004;24:816–23. doi: 10.1161/01.ATV.0000122852.22604.78
- 12 10. Whiting PH, Kalansooriya A, Holbrook I, Haddad F, Jennings PE. The relationship
13 between chronic glycaemic control and oxidative stress in type 2 diabetes mellitus. *Br J*
14 *Biomed Sci.* 2008;65:71–74. doi: 10.1080/09674845.2008.11732800
- 15 11. Reddy MA, Natarajan R. Role of epigenetic mechanisms in the vascular complications
16 of diabetes. *Subcell Biochem.* 2013;61:435–454. doi: 10.1007/978-94-007-4525-4_19
- 17 12. Miao F, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, et al. Evaluating the role of
18 epigenetic histone modifications in the metabolic memory of type 1 diabetes. *Diabetes.*
19 2014;63:1460-. doi: 10.2337/db13-1251
- 20 13. Wegner M, Neddermann D, Piorunska-Stolzmann M, Jagodzinski PP. Role of
21 epigenetic mechanisms in the development of chronic complications of diabetes. *Diabetes*
22 *Res Clin Pract.* 2014 ;105: 164–75. doi: 10.1016/j.diabres.2014.03.019

- 1 14. Liu T, Gong J, Chen Y, Jiang S. Periodic vs constant high glucose in inducing pro-
2 inflammatory cytokine expression in human coronary artery endothelial cells. *Inflamm Res*.
3 2013;62: 697–701. doi: 10.1007/s00011-013-0623-2
- 4 15. Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose-induced expression of
5 proinflammatory cytokine and chemokine genes in monocytic cells. *Diabetes*. 2003;52:
6 1256–1264. doi: 10.2337/diabetes.52.5.1256
- 7 16. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of
8 Intensive Glucose Control in Type 2 Diabetes. *N Engl J Med*. 2008 Oct 9;359:1577–1589.
9 doi: 10.1056/NEJMoa0806470
- 10 17. Kowluru RA, Kanwar M, Kennedy A. Metabolic memory phenomenon and
11 accumulation of peroxynitrite in retinal capillaries. *Exp Diabetes Res*. 2007;2007:21976.
12 doi: 10.1155/2007/21976
- 13 [1847](#). [Fiorello ML, Treweeke AT, Macfarlane DP, Megson IL. The impact of glucose](#)
14 [exposure on bioenergetics and function in a cultured endothelial cell model and the](#)
15 [implications for cardiovascular health in diabetes. *Sci Rep*. 2020;10: 19457.](#)
16 [10.1038/s41598-020-76505-4](#)
- 17
- 18 [198](#). Gaby AR. Adverse effects of dietary fructose. *Alternative Medicine Review*. 2006;10:
19 294–306.
- 20 [2049](#). Atkinson FS, Foster-Powell K, Brand-Miller JC. International tables of glycemic index
21 and glycemic load values. *Diabetes Care*. 2008;31:2281–2283. doi: 10.2337/dc08-1239
- 22 [219](#). Crapo PA, Kolterman OG, Olefsky JM. Effects of oral fructose in normal, diabetic, and

Formatted: Indent: Left: 0 cm, First line: 0 cm

1 impaired glucose tolerance subjects. *Diabetes Care*. 1980;3:575–581. doi:
2 10.2337/diacare.3.5.575

3 [224](#). Anderson JW, Story LJ, Zettwoch NC, Gustafson NJ, Jefferson BS. Metabolic effects of
4 fructose supplementation in diabetic individuals. *Diabetes Care*. 1989;12:337–344. doi:
5 10.2337/diacare.12.5.337

6 [232](#). Tappy L, Lê KA, Tran C, Paquot N. Fructose and metabolic diseases: New findings,
7 new questions. *Nutrition*. 2010;26:1044–1049. doi: 10.1016/j.nut.2010.02.014

8 [243](#). Pereira RM, Botezelli JD, da Cruz Rodrigues KC, Mekary RA, Cintra DE, Pauli JR, et al.
9 Fructose consumption in the development of obesity and the effects of different protocols
10 of physical exercise on the hepatic metabolism. *Nutrients*. 2017;9: 405. doi:
11 10.3390/nu9040405

12 [254](#). Delarue J, Normand S, Pachiardi C, Beylot M, Lamisse F, Riou JP. The contribution of
13 naturally labelled 13C fructose to glucose appearance in humans. *Diabetologia*.
14 1993;36(4):338–345. doi: 10.1007/BF00400238

15 [265](#). Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. Fructose as a key player in the
16 development of fatty liver disease. *World J Gastroenterol*. 2013 ;19:1166–1172. doi:
17 10.3748/wjg.v19.i8.1166

18 [276](#). Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in
19 beverages may play a role in the epidemic of obesity. *Am J Clin Nutrition* 2004;79: 537–
20 543. doi: 10.1093/ajcn/79.4.537

21 [287](#). Sotokawauchi A, Matsui T, Higashimoto Y, Yamagishi S. Fructose causes endothelial
22 cell damage via activation of advanced glycation end products–receptor system. *Diabetes*

- 1 Vasc Dis Res. 2019;16:556–561. doi: 10.1177/1479164119866390
- 2 [298](#). Takeuchi M, Iwaki M, Takino JI, Shirai H, Kawakami M, Bucala R, et al. Immunological
3 detection of fructose-derived advanced glycation end-products. *Lab Investig.*
4 2010;90:1117–1127.
- 5 [3029](#). Dhar A, Desai K, Kazachmov M, Yu P, Wu L. No Title. *Metabolism: Clinical and*
6 *Experimental Sep*, 2008 p. 1211–20. doi: 10.1038/labinvest.2010.62
- 7 [319](#). Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in
8 liver ATP homeostasis in human nonalcoholic steatohepatitis: A pilot study. *J Am Med*
9 *Assoc.* 1999;282: 1659-1664. doi: 10.1001/jama.282.17.1659
- 10 [324](#). Jia G, Aroor AR, Whaley-Connell AT, Sowers JR. Fructose and uric acid: is there a role
11 in endothelial function? *Curr Hypertens Rep.* 2014;16:434. doi: 10.1007/s11906-014-0434-
12 z
- 13 [332](#). Nair S, Chacko VP, Arnold C, Diehl AM. Hepatic ATP reserve and efficiency of
14 replenishing: Comparison between obese and nonobese normal individuals. *Am J*
15 *Gastroenterol.* 2003; 98:466-470. doi: 10.1111/j.1572-0241.2003.07221.x.
- 16 [343](#). Bantle JP. Dietary Fructose and Metabolic Syndrome and Diabetes. *J Nutr.*
17 2009;139(6):1263S-1268S. doi: 10.3945/jn.108.098020
- 18 [354](#). Baena M, Sangüesa G, Dávalos A, Latasa MJ, Sala-Vila A, Sánchez RM, et al. Fructose,
19 but not glucose, impairs insulin signaling in the three major insulin-sensitive tissues. *Sci*
20 *Rep.* 2016; 6: 26149. doi: 10.1038/srep26149
- 21 [365](#). Tappy L, Lê K-AA. Does fructose consumption contribute to non-alcoholic fatty liver
22 disease?. *Clinics and Research in Hepatology and Gastroenterology Masson*; 2012: 36554–

1 560. doi: 10.1016/j.clinre.2012.06.005

2 [376](#). Chiu S, Sievenpiper JL, de Souza RJ, Cozma AI, Mirrahimi A, Carleton AJ, et al. Effect
3 of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review
4 and meta-analysis of controlled feeding trials. *Eur J Clin Nutr.* 2014 ;68:416–423. doi:
5 10.1038/ejcn.2014.8

6 [387](#). Teff KL, Grudziak J, Townsend RR, Dunn TN, Grant RW, Adams SH, et al. Endocrine
7 and metabolic effects of consuming fructose- and glucose-sweetened beverages with
8 meals in obese men and women: Influence of insulin resistance on plasma triglyceride
9 responses. *J Clin Endocrinol Metab.* 2009;94: 1562–1569. doi: 10.1210/jc.2008-2192

10 [398](#). Theytaz F, de Giorgi S, Hodson L, Stefanoni N, Rey V, Schneiter P, et al. Metabolic
11 fate of fructose ingested with and without glucose in a mixed meal. *Nutrients.* 2014 ;6:
12 2632–2649. doi: 10.3390/nu6072632

13 [4039](#). Crescenzo R, Bianco F, Falcone I, Coppola P, Liverini G, Iossa S. Increased hepatic de
14 novo lipogenesis and mitochondrial efficiency in a model of obesity induced by diets rich in
15 fructose. *Eur J Nutr.* 2013;52:537–45. doi: 10.1007/s00394-012-0356-y

16 [410](#). Hirahatake KM, Meissen JK, Fiehn O, Adams SH. Comparative Effects of Fructose and
17 Glucose on Lipogenic Gene Expression and Intermediary Metabolism in HepG2 Liver Cells.
18 Hamel FG, editor. *PLoS One.* 2011;6:e26583. doi: 10.1371/journal.pone.0026583

19 [424](#). Macdonald I, Keyser A, Pacy D. Some effects, in man, of varying the load of glucose,
20 sucrose, fructose, or sorbitol on various metabolites in blood. *Am J Clin Nutr.* 1978;31:
21 1305–1311. doi: 10.1093/ajcn/31.8.1305

22 [432](#). Bohannon N V, Karam JH, Forsham PH. Endocrine responses to sugar ingestion in

- 1 man. Advantages of fructose over sucrose and glucose. *J Am Diet Assoc.* 1980;76: 555–560.
- 2 443. Glushakova O, Kosugi T, Roncal C, Mu W, Heinig M, Cirillo P, et al. Fructose induces
3 the inflammatory molecule ICAM-1 in endothelial cells. *J Am Soc Nephrol.* 2008;19: 1712–
4 20. doi: 10.1681/ASN.2007121304
- 5 454. Cirillo P, Pellegrino G, Conte S, Maresca F, Pacifico F, Leonardi A, et al. Fructose
6 induces prothrombotic phenotype in human endothelial cells. *J Thromb Thrombolysis.*
7 2015;40:444–51. 10.1007/s11239-015-1243-1
- 8 465. Saygin M, Asci H, Cankara FN, Bayram D, Yesilot S, Candan IA, et al. The impact of
9 high fructose on cardiovascular system: Role of α -lipoic acid. *Hum Exp Toxicol.* 2016;35:
10 194-204. doi: 10.1177/0960327115579431
- 11 476. Park K-H, Kim J-Y, Choi I, Kim J-R, Won KC, Cho K-H. Fructated apolipoprotein A-I
12 exacerbates cellular senescence in human umbilical vein endothelial cells accompanied by
13 impaired insulin secretion activity and embryo toxicity. *Biochem Cell Biol* [\[Internet\]](#).
14 2016;94: 337–345. doi: 10.1139/bcb-2015-0165
- 15 ~~47. Fiorillo ML, Treweeke AT, Macfarlane DP, Megson IL. The impact of glucose~~
16 ~~exposure on bioenergetics and function in a cultured endothelial cell model and the~~
17 ~~implications for cardiovascular health in diabetes. *Sci Rep.* 2020;10: 19457.~~
18 ~~10.1038/s41598-020-76505-4~~
- 19 48. Palanisamy N, Venkataraman AC. Beneficial effect of genistein on lowering blood
20 pressure and kidney toxicity in fructose-fed hypertensive rats. *Br J Nutr.* 2013;109:1806–
21 1812. doi: 10.1017/S0007114512003819
- 22 49. Miatello R, Risler N, Castro C, Cruzado M, González S, Zumino AP. Chronic

- 1 administration of losartan reverses cardiovascular changes in hypertensive fructose-fed
2 rats. *Cell Mol Biol.* 2003 ;49:9 45–52.
- 3 50. Singh RB, Mengi SA, Xu Y-J, Arneja AS, Dhalla NS. Pathogenesis of atherosclerosis: A
4 multifactorial process. *Exp Clin Cardiol.* 2002;7: 40–53.
- 5 51. Förstermann U. Nitric oxide and oxidative stress in vascular disease. Vol. 459,
6 *Pflugers Archiv European Journal of Physiology.* 2010.459 923–39. doi: 10.1007/s00424-
7 010-0808-2
- 8 52. Tran LT, Yuen VG, McNeill JH. The fructose-fed rat: A review on the mechanisms of
9 fructose-induced insulin resistance and hypertension. *Mol Cell Biochem.* 2009;332: 145-
10 159. doi: 10.1007/s11010-009-0184-4
- 11 53. Jornayvaz FR, Shulman GI. Regulation of mitochondrial biogenesis. *Essays Biochem.*
12 2010;47:69–84. doi: 10.1042/bse0470069
- 13 54. Lackner LL. Shaping the dynamic mitochondrial network. Vol. 12, *BMC Biology.* 2014;
14 12: 35. doi: 10.1186/1741-7007-12-35
- 15 55. Dobrina A, Rossi F. Metabolic properties of freshly isolated bovine endothelial cells.
16 *BBA - Mol Cell Res.* 1983;762: 295–301. doi: 10.1016/0167-4889(83)90084-8
- 17 56. Koziel A, Woyda-Ploszczyca A, Kicinska A, Jarmuszkiewicz W. The influence of high
18 glucose on the aerobic metabolism of endothelial EA.hy926 cells. *Pflugers Arch Eur J*
19 *Physiol.* 2012;464:657–669. doi: 10.1007/s00424-012-1156-1
- 20 57. Hammad N, Rosas-Lemus M, Uribe-Carvajal S, Rigoulet M, Devin A. The Crabtree and
21 Warburg effects: Do metabolite-induced regulations participate in their induction?
22 *Biochim Biophys Acta - Bioenerg.* 2016;1857: 1139–1146. doi:

- 1 10.1016/j.bbabbio.2016.03.034
- 2 58. Pircher A, Treps L, Bodrug N, Carmeliet P. Endothelial cell metabolism: A novel player
3 in atherosclerosis? Basic principles and therapeutic opportunities. *Atherosclerosis*. 2016;
4 253: 247–257. doi: 10.1016/j.atherosclerosis.2016.08.011
- 5 59. Eelen G, de Zeeuw P, Treps L, Harjes U, Wong BW, Carmeliet P. Endothelial Cell
6 Metabolism. *Physiol Rev* . 2018;98: 3–58. doi: 10.1152/physrev.00001.2017
- 7 60. Abdelmalek MF, Lazo M, Horska A, Bonekamp S, Lipkin EW, Balasubramanyam A, et
8 al. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate
9 homeostasis in obese individuals with type 2 diabetes. *Hepatology*. 2012; 56: 952-960.
10 doi: 10.1002/hep.25741
- 11 61. Hardie DG. AMP-activated protein kinase-an energy sensor that regulates all aspects
12 of cell function. *Genes Dev*. 2011;25:1895–1908. doi: 10.1101/gad.17420111
- 13 62. Garcia D, Shaw RJ. AMPK: Mechanisms of cellular energysensing and restoration of
14 metabolic balance. , *Mol Cell*. 2017;66:789–800. doi: 10.1016/j.molcel.2017.05.032
- 15 63. Ruderman NB, Saha AK, Vavvas D, Witters LA. Malonyl-CoA, fuel sensing, and insulin
16 resistance. *Am J Physiol*. 1999;276:E1–E18. doi: 10.1152/ajpendo.1999.276.1.E1
- 17 64. Velasco G, Geelen MJH, Guzmán M. Control of hepatic fatty acid oxidation by 5'-
18 AMP-activated protein kinase involves a malonyl-CoA-dependent and a malonyl-CoA-
19 independent mechanism. *Arch Biochem Biophys*. 1997;337: 169–175. doi:
20 10.1006/abbi.1996.9784
- 21 65. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, et al.
22 Sugar, uric acid, and the etiology of diabetes and obesity. *Diabetes*. 2013;62: 3307–3315.

1 doi: 10.2337/db12-1814

2 66. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: Molecular
3 mechanisms and pathophysiological implications. *J Physiol.* 2004; 555: 589-606. doi:
4 10.1113/jphysiol.2003.055913

5 67. Matsumoto S, Koshiishi I, Inoguchi T, Nawata H, Utsumi H. Confirmation of
6 Superoxide Generation via Xanthine Oxidase in Streptozotocin-induced Diabetic Mice. *Free*
7 *Radic Res.* 2003;37: 767–72. doi: 10.1080/1071576031000107344

8 68. Butler R, Morris AD, Belch JJFF, Hill A, Struthers AD, R. B, et al. Allopurinol normalizes
9 endothelial dysfunction in type 2 diabetics with mild hypertension. *Hypertension.* 2000;35:
10 746–751. doi: 10.1161/01.hyp.35.3.746

11 69. Desco MC, Asensi M, Márquez R, Martínez-Valls J, Vento M, Pallardó F V., et al.
12 Xanthine oxidase is involved in free radical production in type 1 diabetes: Protection by
13 allopurinol. *Diabetes.* 2002;51: 1118–1124. doi: 10.2337/diabetes.51.4.1118

14 70. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt D V, Reaveley DA, et al.
15 Effects of xanthine oxidase inhibition with allopurinol on endothelial function and
16 peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2
17 placebo-controlled studies. *Circulation.* 2002;105: 2619–2624. doi:
18 10.1161/01.cir.0000017502.58595.ed

19 71. Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical effects of xanthine
20 oxidase inhibitors in hyperuricemic patients. *Med Princ Pract.* 2020 ;30: 122-130. doi:
21 10.1159/000512178

22 72. Nelson D, Cox M. *Lehninger principles of biochemistry (4th ed.):* Freeman &
23 Company, New York, 2005.

- 1 73. Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D. The pentose phosphate
2 pathway: An antioxidant defense and a crossroad in tumor cell fate. *Free Radic Biol Med.*
3 2012; 53: 421–436. doi: 10.1016/j.freeradbiomed.2012.05.006
- 4 74. Chatham JC, Nöt LG, Fülöp N, Marchase RB. Hexosamine biosynthesis and protein O-
5 glycosylation: the first line of defense against stress, ischemia, and trauma. *Shock.*
6 2008;29: 431–440. doi: 10.1097/shk.0b013e3181598bad
- 7 75. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits
8 endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. *J*
9 *Clin Invest.* 2001;108: 1341–1348. doi: 10.1172/JCI11235
- 10 76. Cheng J, Nanayakkara G, Shao Y, Cueto R, Wang L, Yang WY, et al. Mitochondrial
11 proton leak plays a critical role in pathogenesis of cardiovascular diseases. In: *Advances in*
12 *Experimental Medicine and Biology.* Springer New York LLC; 2017. p. 359–370.
- 13 77. Lidington EA, Moyes DL, McCormack AMA, Rose MLM. A comparison of primary
14 endothelial cells and endothelial cell lines for studies of immune interactions. *Transpl*
15 *Immunol.* 1999;7: 239–246. doi: 10.1016/s0966-3274(99)80008-2
- 16 78. Hernestål-Boman J, Norberg M, Jansson J-H, Eliasson M, Eriksson JW, Lindahl B, et al.
17 Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a
18 population-based study. *Cardiovasc Diabetol.* 2012;11: 152. doi: 10.1186/1475-2840-11-
19 152
- 20 79. Ferraris RP, Choe J, Patel CR. Intestinal absorption of fructose. *Annu Rev Nutr.* 2018;
21 38: 41-67. doi: 10.1146/annurev-nutr-082117-051707
- 22 80. Gaudreault N, Scriven DRL, Laher I, Moore EDW. Subcellular characterization of
23 glucose uptake in coronary endothelial cells. *Microvasc Res.* 2008;75:73–82. doi:

1 10.1016/j.mvr.2007.04.006

2